Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 69fludarabine phosphate 63Busulfan 45Peripheral Blood Stem Cell Transplantation 42Tacrolimus 40Mycophenolic Acid 37Filgrastim 35Antilymphocyte Serum 35fludarabine 31Cyclosporine 30Radiotherapy 29Melphalan 29Whole-Body Irradiation 27Methotrexate 24Etoposide 20Cord Blood Stem Cell Transplantation 18Biopsy 18Methylprednisolone 16Specimen Handling 15Rituximab 14Magnetic Resonance Spectroscopy 13Alemtuzumab 12Stem Cell Transplantation 11Granulocyte Colony-Stimulating Factor 11Cytarabine 11sargramostim 9Sirolimus 9Prednisone 9Dexamethasone 9plerixafor 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Glycopeptides × Plasma cell × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡